总裁, 首席执行官
Clay B. Siegall, Ph.D. is an American biopharmaceutical executive serving as President, Chief Executive Officer, and Chairman of Immunome Inc. (NASDAQ: IMNM) since October 2, 2023, following the merger with Morphimmune, where he was also President and CEO.[[1]](https://www.zoominfo.com/p/Clay-Siegall/5740410596)[[2]](https://fintool.com/app/research/companies/IMNM/people/clay-siegall)[[3]](https://www.shattucklabs.com/clay-siegall/) Age 64, Dr. Siegall is a recognized leader in oncology drug development, particularly antibody-drug conjugates (ADCs).[[3]](https://www.shattucklabs.com/clay-siegall/)[[5]](https://lifesciencewa.org/speakers/clay-siegall-phd/)
Dr. Siegall co-founded Seagen Inc. (formerly Seattle Genetics) in 1997, serving as CEO (2002–2022), President (2000–2022), and Chairman (2004–2022), transforming it into a global leader in ADC therapeutics with four FDA-approved cancer therapies, over $2 billion in annual revenue, and its $43 billion acquisition by Pfizer in 2023.[[1]](https://www.zoominfo.com/p/Clay-Siegall/5740410596)[[2]](https://fintool.com/app/research/companies/IMNM/people/clay-siegall)[[3]](https://www.shattucklabs.com/clay-siegall/)[[5]](https://lifesciencewa.org/speakers/clay-siegall-phd/) Earlier, he held roles at Bristol-Myers Squibb Pharmaceutical Research Institute (1991–1997) and the National Cancer Institute (1988–1991).[[1]](https://www.zoominfo.com/p/Clay-Siegall/5740410596)[[2]](https://fintool.com/app/research/companies/IMNM/people/clay-siegall)[[4]](https://www.youtube.com/watch?v=ZKJdQxD80A8) He holds a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland.[[1]](https://www.zoominfo.com/p/Clay-Siegall/5740410596)[[2]](https://fintool.com/app/research/companies/IMNM/people/clay-siegall)[[4]](https://www.youtube.com/watch?v=ZKJdQxD80A8) Currently, he chairs the boards of Tourmaline Bio and serves as a director at Shattuck Labs, among other roles.[[2]](https://fintool.com/app/research/companies/IMNM/people/clay-siegall)
查看完整内部人档案 →